437 related articles for article (PubMed ID: 28338503)
41. Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
Yang S; Zhang H; Yang P; Wang C; Wu Q
J Cardiovasc Pharmacol; 2021 May; 77(5):650-659. PubMed ID: 33951700
[TBL] [Abstract][Full Text] [Related]
42. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Senni M; McMurray JJ; Wachter R; McIntyre HF; Reyes A; Majercak I; Andreka P; Shehova-Yankova N; Anand I; Yilmaz MB; Gogia H; Martinez-Selles M; Fischer S; Zilahi Z; Cosmi F; Gelev V; Galve E; Gómez-Doblas JJ; Nociar J; Radomska M; Sokolova B; Volterrani M; Sarkar A; Reimund B; Chen F; Charney A
Eur J Heart Fail; 2016 Sep; 18(9):1193-202. PubMed ID: 27170530
[TBL] [Abstract][Full Text] [Related]
43. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J
Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583
[TBL] [Abstract][Full Text] [Related]
45. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
[TBL] [Abstract][Full Text] [Related]
46. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
47. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
Ito S; Satoh M; Tamaki Y; Gotou H; Charney A; Okino N; Akahori M; Zhang J
Hypertens Res; 2015 Apr; 38(4):269-75. PubMed ID: 25693859
[TBL] [Abstract][Full Text] [Related]
48. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).
Chung WB; Ihm SH; Jang SW; Her SH; Park CS; Lee JM; Chang K; Jeon DS; Yoo KD; Seung KB
Drug Des Devel Ther; 2020; 14():347-360. PubMed ID: 32158190
[TBL] [Abstract][Full Text] [Related]
49. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
50. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials.
Wu HX; Liu KK; Li BN; Liu S; Jin JC
Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers.
Fuenfstueck R; Hempel RD; Ansari A; Weidinger G; Klebs S
Adv Ther; 2005; 22(3):263-77. PubMed ID: 16236687
[TBL] [Abstract][Full Text] [Related]
53. Effects of Low-Dose Sacubitril/Valsartan on Different Stages of Cardiac Hypertrophy in Salt-Loaded Hypertensive Rats.
Hamano G; Yamamoto K; Takami Y; Takeshita H; Shimosato T; Moritani T; Rakugi H
J Cardiovasc Pharmacol; 2019 May; 73(5):282-289. PubMed ID: 30829732
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
[TBL] [Abstract][Full Text] [Related]
55. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.
Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y
J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964
[TBL] [Abstract][Full Text] [Related]
57. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
58. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
59. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
60. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
